← All trials
NCT06364852
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 25, 2021
- Primary completion
- Aug 31, 2024
- Completion date
- May 31, 2026
- First posted
- Apr 15, 2024
- Last posted
- Apr 15, 2024
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiao Tong UniversityLead sponsor
- Jiao Tong UniversityOfficial
- Jiao Tong UniversitySponsor investigator
- Shanghai Longyao Biotechnology Inc., Ltd.Collaborator
- Nanjing Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.